Xenon Pharmaceuticals (XENE) Set to Announce Earnings on Thursday

Xenon Pharmaceuticals (NASDAQ:XENE) will post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Xenon Pharmaceuticals to post earnings of ($0.69) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.12. During the same quarter last year, the company posted ($0.57) earnings per share. Xenon Pharmaceuticals’s revenue for the quarter was up .0% compared to the same quarter last year. On average, analysts expect Xenon Pharmaceuticals to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Xenon Pharmaceuticals Stock Up 0.6 %

Shares of XENE opened at $43.43 on Wednesday. The stock’s 50 day moving average is $43.06 and its two-hundred day moving average is $41.50. Xenon Pharmaceuticals has a twelve month low of $27.99 and a twelve month high of $50.99.

Insider Activity

In related news, Director Steven Gannon sold 13,000 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $46.28, for a total transaction of $601,640.00. Following the completion of the transaction, the director now directly owns 2,000 shares in the company, valued at approximately $92,560. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Steven Gannon sold 13,000 shares of the business’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $46.28, for a total value of $601,640.00. Following the completion of the transaction, the director now owns 2,000 shares of the company’s stock, valued at approximately $92,560. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sherrington Robin sold 7,137 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $46.28, for a total transaction of $330,300.36. Following the completion of the transaction, the executive vice president now owns 8,398 shares in the company, valued at $388,659.44. The disclosure for this sale can be found here. Company insiders own 5.43% of the company’s stock.

Analyst Ratings Changes

XENE has been the subject of several research analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $62.00 price objective on shares of Xenon Pharmaceuticals in a research report on Friday, April 12th. Royal Bank of Canada reduced their price objective on shares of Xenon Pharmaceuticals from $56.00 to $55.00 and set an “outperform” rating for the company in a research note on Friday, March 1st. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 target price on shares of Xenon Pharmaceuticals in a research report on Wednesday, April 10th. Finally, Wedbush lifted their price target on shares of Xenon Pharmaceuticals from $46.00 to $51.00 and gave the company an “outperform” rating in a research report on Friday, March 1st. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. According to MarketBeat, Xenon Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $59.44.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.